Author: Epeius Biotechnologies Corporation
-
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
freeNewsArticles Story Summary: SAN MARINO, Calif. – Dec. 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled ‘In Vivo Barriers to Gene…
-
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G, a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
freeNewsArticles Story Summary: SAN MARINO, Calif. – Dec. 17 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum…
-
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
freeNewsArticles Story Summary: SAN MARINO, Calif. – Nov. 5 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G…
-
Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G(TM) as Treatment for Diverse Metastatic Cancers
freeNewsArticles Story Summary: SAN MARINO, Calif. and TOKYO, Japan – Dec. 6 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October,…
-
Epeius Biotechnologies Initiates Tri-REX Vaccination Protocols for Breast Cancer
freeNewsArticles Story Summary: SAN MARINO, CA and MANILA, Philippines – July 5 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the opening of a Vaccine-assisted Phase I/II clinical trial for metastatic breast cancer that is refractory to conventional chemotherapy. The innovative protocol introduces Reximmune-C(TM), the second in a series of targeted biologic therapies designed to seek…
-
Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer
freeNewsArticles Story Summary: SAN MARINO, CA – June 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.
-
Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies
freeNewsArticles Story Summary: SAN MARINO, CA – Apr. 7 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the…